ABSI vs RLAY
ABSI and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | $1.66B | $3.78B |
| P/S | 644.8x | 250.4x |
| Revenue growth (YoY) | -38.2% | 53.4% |
| Earnings growth (YoY) | -11.7% | 18.1% |
| EBIT margin | -4297.0% | -1971.6% |
| ROE | -46.8% | -31.1% |
| ROIC | -84.6% | — |
| 1y total return | +145.2% | +146.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABSI vs RLAY
| Metric | ABSI | RLAY |
|---|---|---|
| End value | $4.5K | $5.0K |
| Total return | -55.1% | -49.5% |
| CAGR | -14.1% | -12.2% |
| Volatility | 98.3% | 77.3% |
| Sharpe | 0.29 | 0.16 |
| Sortino | 0.44 | 0.24 |
| Max drawdown | -96.2% | -94.7% |
Based on 1327 common trading days, 2021-07-22 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)